Sted:<\/strong> Hilton at UAB Downtown<\/p>\nFredag 1. mai 2026<\/strong>
\nMedisinsk symposium: <\/strong>08:00\u201317:00
\nSted:<\/strong> Marnix E. Heersink Conference Center ved University of Alabama at Birmingham
\nMedisinsk mottakelse for symposium: <\/strong>18:00\u201320:00
\nSted:<\/strong> Marnix E. Heersink Conference Center ved University of Alabama at Birmingham<\/p>\nL\u00f8rdag 2. mai 2026<\/strong>
\nM\u00f8te for ECD-behandlingssentre: <\/strong>08:00\u201311:00
\nSted:<\/strong> UAB Cancer Center<\/p>\nDette arrangementet vil samle det globale Erdheim-Chester-samfunnet med ledende medisinske eksperter for \u00e5 dele den nyeste forskningen, klinisk innsikt og samfunnsressurser. Deltakerne kan forvente seg l\u00e6rerike sesjoner, muligheter til \u00e5 komme i kontakt med fagfeller og oppdateringer om nye behandlingsformer og pasientbehandling.<\/p>\n
Ytterligere detaljer om hotellet og h\u00f8ydepunktene i programmet vil bli offentliggjort i l\u00f8pet av de kommende m\u00e5nedene.<\/p>\n
Dagsorden<\/h2>\n\n
\n\n\n\t| Time<\/th> | Subject<\/th> | Presenter<\/th>\n<\/tr>\n<\/thead>\n |
\n\n\t| 8:00 am<\/td> | Registration & light breakfast<\/td> | <\/td>\n<\/tr>\n |
\n\t| 8:30 am<\/td> | Welcome to Birmingham and the 11th Annual Erdheim-Chester Disease International Conference<\/td> | Gaurav Goyal<\/strong>
\nUniversity of Alabama at Birmingham, Birmingham, AL USA<\/td>\n<\/tr>\n\n\tKeynote Address<\/strong><\/td>\n<\/tr>\n\n\t| 8:45 am <\/td> | Diversity and Degeneration in
\nNeurohistiocytic Disease<\/td> | Nicole Coufal<\/strong>
\nUniversity of California, San Diego
\nUSA<\/td>\n<\/tr>\n\n\t| 9:25 am<\/td> | Break<\/td>\n<\/tr>\n | \n\tMorning Abstract Presentations Session 1: Cells, Clones & Circuits: Where Histiocytosis Begins (and Persists)<\/strong><\/td>\n<\/tr>\n\n\t| 9:35 am<\/td> | ARAF Mutations Drive Histiocytic Neoplasms
\nIn Vivo and Provide Insights into Cellular
\nOrigin<\/td> | Benjamin Durham<\/strong>
\nRutgers Cancer Institute, Robert
\nWood Johnson School of Medicine,
\nBrunswick, NJ<\/td>\n<\/tr>\n\n\t| 9:50 am<\/td> | Tracking BRAF V600E Persistence under MEK
\nInhibition in Histiocytoses: a B-cell\u2013enriched
\nsignal<\/td> | Julien Haroche<\/strong>
\nDepartment of Internal Medicine &
\nE3M Institute, Piti\u00e9-Salp\u00eatri\u00e8re
\nHospital, AP-HP \u2013 Sorbonne
\nUniversity, Paris, France<\/td>\n<\/tr>\n\n\t| 10:05 am<\/td> | Distribution of MAP2K1 Variants Across
\nPeripheral Blood Cells in Erdheim-Chester
\nDisease and Other Histiocytoses<\/td> | Irena Ungureanu<\/strong>
\nAmbroise-Par\u00e9 Hospital, Pathology
\nDepartment, Boulogne-Billancourt,
\nFrance<\/td>\n<\/tr>\n\n\t| 10:20 am<\/td> | The Clonal Origin and Evolution of High-Risk
\nMultisystem Histiocytosis in Adults<\/td> | Matthew Collin<\/strong>
\nNewcastle University, United
\nKingdom<\/td>\n<\/tr>\n\n\t| 10:35 am<\/td> | Networking Break<\/td>\n<\/tr>\n | \n\tMorning Abstract Presentations Session 2: Genotype \u2192 Therapy: Biomarkers, Responses, and New Vulnerabilities<\/strong><\/td>\n<\/tr>\n\n\t| 10:50 am<\/td> | KRAS Mutations in Histiocytic Neoplasms:
\nMutation Spectrum and Response to MEK
\nInhibition<\/td> | Dongni Yi<\/strong>
\nMayo Clinic, Rochester, MN USA<\/td>\n<\/tr>\n\n\t| 11:05 am<\/td> | Cyclin D1 Overexpression Drives Replication
\nStress and Creates Therapeutic
\nVulnerabilities in Histiocytic Neoplasms<\/td> | Dongni Yi<\/strong>
\nMayo Clinic, Rochester, MN USA<\/td>\n<\/tr>\n\n\t| 11:20 am<\/td> | Clonal Hematopoiesis Predicts Response to
\nInterferon-\u03b1 in Erdheim-Chester Disease and
\nMyeloproliferative Neoplasms<\/td> | J\u00e9r\u00f4me Razanamahery<\/strong>
\nDijon University Hospital, France<\/td>\n<\/tr>\n\n\t| 11:35 am<\/td> | Impact of Additional Genetic Variants in the
\nCourse of Erdheim-Chester Disease\u2026 a
\nMulticentric Longitudinal Study of 445 French
\nPatients<\/td> | F\u00e9licien Triboulet<\/strong>
\nPiti\u00e9-Salp\u00eatri\u00e8re hospital, Sorbonne
\nUniversity, Paris, France<\/td>\n<\/tr>\n\n\t| 11:50 am<\/td> | Group Photo<\/td> | <\/td>\n<\/tr>\n | \n\t| 12:00 pm<\/td> | Lunch<\/td>\n<\/tr>\n | \n\tAfternoon Abstract Presentations Session 3: Pixels to Patterns: ECD and Xanthogranuloma<\/strong><\/td>\n<\/tr>\n\n\t| 1:00 pm<\/td> | Central Nervous System Imaging
\nAbnormalities in Erdheim\u2013Chester Disease: A
\nSystematic Review<\/td> | Mustafa Abomohsen<\/strong>
\nBrookdale University Hospital and
\nMedical Center, Brooklyn, NY USA<\/td>\n<\/tr>\n\n\t| 1:15 pm<\/td> | Musculoskeletal System Imaging
\nAbnormalities in Erdheim\u2013Chester Disease: A
\nSystematic Review<\/td> | Mustafa Abomohsen<\/strong>
\nBrookdale University Hospital and
\nMedical Center, Brooklyn, NY USA<\/td>\n<\/tr>\n\n\t| 1:30 pm<\/td> | Patterns of Presentation and Outcomes in
\nAdult Xanthogranuloma<\/td> | Guneet Janda<\/strong>
\nMayo Clinic, Rochester, MN USA<\/td>\n<\/tr>\n\n\t| 1:45 pm<\/td> | Networking Break<\/td>\n<\/tr>\n | \n\tAfternoon Abstract Presentations Session 4: Care in the Real World: Treatment Patterns and Survivorship<\/strong><\/td>\n<\/tr>\n\n\t| 2:00 pm<\/td> | Real World Frontline Systemic Anti-Cancer
\nTreatment Patterns and Outcomes in
\nErdheim\u2013Chester Disease<\/td> | Carla Isabel Borre<\/strong>
\nMayo Clinic, Rochester, MN USA<\/td>\n<\/tr>\n\n\t| 2:15 pm<\/td> | Burden of Chronic Health Conditions After
\nDiagnosis of Erdheim\u2013Chester Disease
\n(ECD): Early Results from the Histiocytic
\nDisorder Survivor Study<\/td> | Gaurav Goyal<\/strong>
\nUniversity of Alabama at
\nBirmingham, Birmingham, AL USA<\/td>\n<\/tr>\n\n\t| 2:30 pm<\/td> | Destombes-Rosai-Dorfman Disease:
\nClinical, Molecular Characteristics and
\nTreatment Response: data from a
\nretrospective cohort of 107 patients<\/td> | Julien Haroche<\/strong>
\nDepartment of Internal Medicine &
\nE3M Institute, Piti\u00e9-Salp\u00eatri\u00e8re
\nHospital, AP-HP \u2013 Sorbonne
\nUniversity, Paris, France<\/td>\n<\/tr>\n\n\t| 2:45 pm<\/td> | Considerations for Assessment and
\nTreatment of Neuropsychiatric Symptoms in
\nECD<\/td> | Anneka Johnston<\/strong>
\nRush University Medical Center,
\nChicago IL<\/td>\n<\/tr>\n\n\tPoster Presentations and Networking<\/strong><\/td>\n<\/tr>\n\n\t| 3:00 pm<\/td> | Erdheim-Chester Disease (ECD) is a Rare
\nHistiocytic Neoplasm of Non-Langerhans
\nCell Histiocytosis<\/td> | Abdalla Bowirrat<\/strong>
\nAriel University, Israel<\/td>\n<\/tr>\n\n\tDiagnostic challenges in mixed ErdheimChester Disease and Langerhans Cell
\nHistiocytosis in a 54-year-old male<\/td> | Sameer Andani<\/strong>
\nMofitt Cancer Center & University
\nof South Florida<\/td>\n<\/tr>\n\n\tA Mycosis Fungoides-like Drug Reaction
\nRapidly Resolving Following Switch from
\nBRAF Inhibitor to MEK Inhibitor Monotherapy
\nin Erdheim-Chester Disease<\/td> | Saipriya Ayyar<\/strong>
\nUniversity of Cincinnati\/UC Health,
\nCincinnati OH<\/td>\n<\/tr>\n\n\tMultimodality Imaging in Erdheim\u2013Chester
\nDisease: Radiologic Insights from Pediatric
\nand Adult Cases<\/td> | Priyanka Naranje<\/strong>
\nAll India Institute of Medical
\nSciences, New Delhi, India<\/td>\n<\/tr>\n\n\tCardiovascular System Imaging
\nAbnormalities in Erdheim-Chester Disease: A
\nSystematic Review<\/td> | Mustafa Abomohsen<\/strong>
\nBrookdale University Hospital and
\nMedical Center, Brooklyn, NY USA<\/td>\n<\/tr>\n\n\tBRAF-Positive Erdheim\u2013Chester Disease with
\nProgressive Pulmonary and Vascular
\nInvolvement Successfully Treated with
\nVemurafenib: A Case Report<\/td> | Hulya Yilmaz Tekinhatun<\/strong>
\nDiyarbakir Gazi Yasargil Training and
\nResearch Hospital, Turkey<\/td>\n<\/tr>\n\n\tConcurrent Erdheim-Chester Disease and
\nClassical Hodgkin Lymphoma with
\nunexpected response to lymphoma-directed
\ntherapy<\/td> | Rebecca Denson<\/strong>
\nNew York Presbyterian-Weill Cornell
\nMedicine, New York, NY<\/td>\n<\/tr>\n\n\tAbdominal Imaging Abnormalities in
\nErdheim-Chester Disease: A Systematic
\nReview<\/td> | Mustafa Abomohsen<\/strong>
\nBrookdale University Hospital and
\nMedical Center, Brooklyn, NY USA<\/td>\n<\/tr>\n\n\tPrevalence and distribution of ErdheimChester Disease in the UK estimated from
\nreferral to a National Advisory Panel<\/td> | Matthew Collin<\/strong>
\nNewcastle University, United
\nKingdom<\/td>\n<\/tr>\n\n\tChallenging Case Study<\/strong><\/td>\n<\/tr>\n\n\t| 3:45 pm<\/td> | All that glitters: retro-orbital
\nxanthogranuloma or ECD?<\/td> | Matthew Collin<\/strong>
\nNewcastle University, United
\nKingdom<\/td>\n<\/tr>\n\n\tChallenging Case Study<\/strong><\/td>\n<\/tr>\n\n\t| 4:15 pm<\/td> | The Clue Was the Blood Pressure: Atypical
\nErdheim\u2013Chester Disease<\/td> | Jithma Abeykoon<\/strong>
\nMayo Clinic, Rochester, MN USA<\/td>\n<\/tr>\n\n\tClosing Remarks & Student Abstract Award<\/strong><\/td>\n<\/tr>\n\n\t| 4:45 pm<\/td> | ECD Global Alliance into the Future<\/td> | Jerome Henson<\/strong>
\nExecutive Director, ECD Global
\nAlliance, DeRidder, LA USA<\/td>\n<\/tr>\n\n\t| 4:55 pm<\/td> | Junior Investigator \u2013 Best Student
\nPresentation Award<\/td> | Oshrat Hershkovitz-Rokah<\/strong>
\nAriel University & Assut<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\nLast ned agenda<\/a><\/span><\/p>\nRegistrer deg<\/a><\/span><\/p>\nMERK:<\/strong> Registrer deg f\u00f8r 1. februar for \u00e5 dra nytte av tidligregistreringskostnaden! Spar 200 USD og registrer deg for bare 300 USD! <\/p>\nMark Heaney Awareness Award & Community Champion Award<\/h3>\n1. februar 2026 – siste dag for \u00e5 sende inn nominasjon til Mark Heaney Awareness Award & Community Champion Award .<\/strong><\/p>\n | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
![\"\"](\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2026\/04\/download.png\")
<\/a><\/div>\n<\/div>\n![\"\"](\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2026\/04\/download-1.png\")
<\/a><\/div>\n<\/div>\n![\"\"](\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2026\/04\/download-2.png\")
<\/a><\/div>\n![\"\"](\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2026\/04\/download-3.png\")
<\/a><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"